Recent Updates
Recently added Catalysts
ALKS Positive Sentiment

Alkermes to Participate in the Jefferies London Healthcare Conference Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Jefferies London Healthcare Conference on...

Tuesday, November 7, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Alkermes plc announced its participation in the Jefferies London Healthcare Conference, scheduled for November 14, 2023. Management will engage in a fireside chat, which will be available via live webcast. The event underscores Alkermes' commitment to investor relations and transparency.
Price reaction · baseline $24.99 (2023-11-06 close) · hit after-hours · clean, no other ALKS news in the window
day 0 close · peak
+1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Alkermes is participating in a notable healthcare conference.
  • The event provides a platform for management to engage with investors.
  • The webcast will be accessible for 14 days, allowing wider audience reach.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+29%
120-day peak, hindsight
Typical move
3.3%
average across 7 past catalysts
Lead asset
N1539
Phase 2 · Hysterectomy

Full Press Release Details

DUBLIN , Nov. 7, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS ) announced today that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, Nov. 14, 2023 at 12:00 p.m. ET ( 5:00 p.m. GMT ). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
About Alkermes plc Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com .

Frequently Asked Questions

When is Alkermes participating in the conference?

Alkermes will participate in the Jefferies London Healthcare Conference on November 14, 2023.

How can I access the Alkermes webcast?

The live webcast can be accessed under the Investors tab on Alkermes' website.

How long will the webcast be available?

The webcast will be archived and available for 14 days.

What is the focus of Alkermes' product portfolio?

Alkermes focuses on innovative medicines for neuroscience and oncology.

ShareAdd on Google
Tags: ALKS Viatris Investor Conferences Healthcare Alkermes Jefferies Conference biopharmaceuticals healthcare investor relations
Last updated: Nov 7, 2023

Biotech snapshot

Cash runway
$691M liquidity · $0M/mo burn
Low dilution risk
Lead asset
N1539Phase 2
Hysterectomy →

Catalyst track record

+29%
best trade around ALKS's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for ALKS.

See every catalyst's timing & PoA →